These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 20336786)
1. Patterns of questionable quality care in nonmuscle invasive bladder cancer. Gore JL; Porter MP Cancer; 2010 Jun; 116(11):2508-10. PubMed ID: 20336786 [No Abstract] [Full Text] [Related]
2. A rationale for developing benchmarks for the treatment of muscle-invasive bladder cancer. Lee CT Urol Oncol; 2007; 25(1):57-65. PubMed ID: 17208141 [TBL] [Abstract][Full Text] [Related]
3. Re: bladder cancer clinical guidelines panel summary report on the management of nonmuscle invasive bladder cancer (stages Ta, T1 AND TIS). Lamm DL J Urol; 2000 Jun; 163(6):1890-1. PubMed ID: 10799217 [No Abstract] [Full Text] [Related]
4. Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancer. Hendricksen K; Witjes JA Curr Opin Urol; 2007 Sep; 17(5):352-7. PubMed ID: 17762630 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of holmium laser resection for primary nonmuscle-invasive bladder cancer versus transurethral electroresection: single-center experience. Zhu Y; Jiang X; Zhang J; Chen W; Shi B; Xu Z Urology; 2008 Sep; 72(3):608-12. PubMed ID: 18649930 [TBL] [Abstract][Full Text] [Related]
6. Understanding bladder cancer death: tumor biology versus physician practice. Morris DS; Weizer AZ; Ye Z; Dunn RL; Montie JE; Hollenbeck BK Cancer; 2009 Mar; 115(5):1011-20. PubMed ID: 19152434 [TBL] [Abstract][Full Text] [Related]
7. [The role of preserving therapy of invasive cancer of the urinary bladder]. Matveev BP; Sallum SD; Kamolov BSh; Figurin KM; Matveev VB; Volkova MI Urologiia; 2005; (6):3-6. PubMed ID: 16419470 [TBL] [Abstract][Full Text] [Related]
8. Quality of bladder cancer care in the USA. Chamie K; Litwin MS Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):619-21. PubMed ID: 22098276 [No Abstract] [Full Text] [Related]
9. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. Zietman AL; Sacco D; Skowronski U; Gomery P; Kaufman DS; Clark JA; Talcott JA; Shipley WU J Urol; 2003 Nov; 170(5):1772-6. PubMed ID: 14532773 [TBL] [Abstract][Full Text] [Related]
10. Health-related quality of life after bladder preservation therapy for muscle invasive bladder cancer. Hashine K; Miura N; Numata K; Shirato A; Sumiyoshi Y; Kataoka M Int J Urol; 2008 May; 15(5):403-6. PubMed ID: 18384578 [TBL] [Abstract][Full Text] [Related]
11. [Management of Ta, T1, and in situ bladder carcinoma: what is new?]. Irani J Prog Urol; 2008 May; 18 Suppl 5():S94-8. PubMed ID: 18585634 [TBL] [Abstract][Full Text] [Related]
12. Loss of heterozygosis on IFN-alpha locus is a prognostic indicator of bacillus Calmette-Guerin response for nonmuscle invasive bladder cancer. Cai T; Nesi G; Dal Canto M; Tinacci G; Mondaini N; Piazzini M; Geppetti P; Bartoletti R J Urol; 2010 May; 183(5):1738-43. PubMed ID: 20299058 [TBL] [Abstract][Full Text] [Related]
14. Optimizing outcomes at every stage of bladder cancer: do we practice it? Herr H; Konety B; Stein J; Sternberg CN; Wood DP Urol Oncol; 2009; 27(1):72-4. PubMed ID: 19111802 [TBL] [Abstract][Full Text] [Related]
15. Bladder-sparing procedure as good as cystectomy for treating invasive bladder cancer. Rollins G Rep Med Guidel Outcomes Res; 2002 Aug; 13(15):7-9. PubMed ID: 12553324 [No Abstract] [Full Text] [Related]